A fast image retrieval method designed for network big data

In the field of big data applications, image information is widely used. The value density of information utilization in big data is very low, and how to extract useful information quickly is very important. So we should transform the unstructured image data source into a form that can be analyzed. In this paper, we proposed a fast image retrieval method which designed for big data. First of all, the feature extraction method is necessary and the feature vectors can be obtained for every image. Then, it is the most important step for us to encode the image feature vectors and make them into database, which can optimize the feature structure. Finally, the corresponding similarity matching is used to determined the retrieval results. There are three main contributions for image retrieval in this paper. New feature extraction method, reasonable elements ranking and appropriate distance metric can improve the algorithm performance. Experiments show that our method has a great improvement in the effective performance of feature extraction and can also get better search matching results

Internet cross-media retrieval based on deep learning

With the development of Internet, multimedia information such as image and video is widely used. Therefore, how to find the required multimedia data quickly and accurately in a large number of resources , has become a research focus in the field of information process. In this paper, we propose a real time internet cross-media retrieval method based on deep learning. As an innovation, we have made full improvement in feature extracting and distance detection. After getting a large amount of image feature vectors, we sort the elements in the vector according to their contribution and then eliminate unnecessary features. Experiments show that our method can achieve high precision in image-text cross media retrieval, using less retrieval time. This method has a great application space in the field of cross media retrieval

No-reference stereoscopic image-quality metric accounting for left and right similarity map and spatial structure degradation

Blind quality assessment of 3D images is used to confront more real challenges than 2D images. In this Letter, we develop a no-reference stereoscopic image quality assessment (SIQA) model based on the proposed left and right (LR)-similarity map and structural degradation. In the proposed method, local binary pattern features are extracted from the cyclopean image that are effective for describing the distortion of 3D images. More importantly, we first propose the LR-similarity map that can indicate the stereopair quality and demonstrate that the use of LR-similarity information results in a consistent improvement in the performance. The massive experimental results on the LIVE 3D and IRCCyN IQA databases demonstrate that the designed model is strongly correlated to subjective quality evaluations and competitive to the state-of-the-art SIQA algorithms

Table_1_Multiple primary malignant neoplasm: Case report and comprehensive literature review.xlsx

Multiple primary tumors, especially quadruple primary tumors, are extremely rare clinically, and there is no standard protocol for clinical management. We described a case in which a bone tumor, a malignant bladder tumor, a malignant melanoma, and an intrahepatic cholangiocarcinoma were all original malignancies. The patient is a 79-year-old woman who underwent surgery for a left middle finger bone tumor 45 years ago, as well as surgery for bladder malignancy and postoperative adjuvant chemotherapy 15 years ago, and the precise pathological results and treatment are unclear. One year ago, she underwent amputation of the toe due to a black mass of the right toe and was diagnosed pathologically as a freckled malignant melanoma of the extremity. Prior to postoperative adjuvant systemic medication, PET/CT revealed malignancy in the lateral segment of the left lobe of the liver, and multiple lymphadenopathies in the left parotid gland, hilar hepatic, and retroperitoneal region. Intrahepatic cholangiocarcinoma was found in the liver puncture biopsy’s pathology report. The serum sample’s next-generation sequencing (NGS) revealed a missense mutation, designated P.G12V, in exon 2 of the KRAS gene. Based on patients with malignant melanoma and intrahepatic cholangiocarcinoma, she received 6 cycles of GP (gemcitabine/cisplatin) combined with Camrelizumab systemic therapy, and followed by 3 cycles of Camrelizumab maintenance therapy, the efficacy was evaluated as stable disease (SD) during treatment. When the 4th cycle of Camrelizumab was suggested for maintenance therapy, the efficacy evaluation revealed that the tumor had greatly advanced. The patient refused to continue anti-tumor therapy and passed away from septic shock and multiple organ failure 3 months later. The patient had satisfactory efficacy and lived for a year after being diagnosed with two primary cancers. Despite the rarity of quadruple primary tumors and the lack of a conventional clinical management strategy, we postulate that germline mutations in the KRAS gene may be closely associated with the formation and development of multiple primary tumors. NGS testing is necessary for clinical management, and systemic treatment based on concurrent multiple main tumors is the key to improving prognosis.</p

DataSheet_1_Multiple primary malignant neoplasm: Case report and comprehensive literature review.docx

Multiple primary tumors, especially quadruple primary tumors, are extremely rare clinically, and there is no standard protocol for clinical management. We described a case in which a bone tumor, a malignant bladder tumor, a malignant melanoma, and an intrahepatic cholangiocarcinoma were all original malignancies. The patient is a 79-year-old woman who underwent surgery for a left middle finger bone tumor 45 years ago, as well as surgery for bladder malignancy and postoperative adjuvant chemotherapy 15 years ago, and the precise pathological results and treatment are unclear. One year ago, she underwent amputation of the toe due to a black mass of the right toe and was diagnosed pathologically as a freckled malignant melanoma of the extremity. Prior to postoperative adjuvant systemic medication, PET/CT revealed malignancy in the lateral segment of the left lobe of the liver, and multiple lymphadenopathies in the left parotid gland, hilar hepatic, and retroperitoneal region. Intrahepatic cholangiocarcinoma was found in the liver puncture biopsy’s pathology report. The serum sample’s next-generation sequencing (NGS) revealed a missense mutation, designated P.G12V, in exon 2 of the KRAS gene. Based on patients with malignant melanoma and intrahepatic cholangiocarcinoma, she received 6 cycles of GP (gemcitabine/cisplatin) combined with Camrelizumab systemic therapy, and followed by 3 cycles of Camrelizumab maintenance therapy, the efficacy was evaluated as stable disease (SD) during treatment. When the 4th cycle of Camrelizumab was suggested for maintenance therapy, the efficacy evaluation revealed that the tumor had greatly advanced. The patient refused to continue anti-tumor therapy and passed away from septic shock and multiple organ failure 3 months later. The patient had satisfactory efficacy and lived for a year after being diagnosed with two primary cancers. Despite the rarity of quadruple primary tumors and the lack of a conventional clinical management strategy, we postulate that germline mutations in the KRAS gene may be closely associated with the formation and development of multiple primary tumors. NGS testing is necessary for clinical management, and systemic treatment based on concurrent multiple main tumors is the key to improving prognosis.</p

DataSheet_2_Multiple primary malignant neoplasm: Case report and comprehensive literature review.zip

Multiple primary tumors, especially quadruple primary tumors, are extremely rare clinically, and there is no standard protocol for clinical management. We described a case in which a bone tumor, a malignant bladder tumor, a malignant melanoma, and an intrahepatic cholangiocarcinoma were all original malignancies. The patient is a 79-year-old woman who underwent surgery for a left middle finger bone tumor 45 years ago, as well as surgery for bladder malignancy and postoperative adjuvant chemotherapy 15 years ago, and the precise pathological results and treatment are unclear. One year ago, she underwent amputation of the toe due to a black mass of the right toe and was diagnosed pathologically as a freckled malignant melanoma of the extremity. Prior to postoperative adjuvant systemic medication, PET/CT revealed malignancy in the lateral segment of the left lobe of the liver, and multiple lymphadenopathies in the left parotid gland, hilar hepatic, and retroperitoneal region. Intrahepatic cholangiocarcinoma was found in the liver puncture biopsy’s pathology report. The serum sample’s next-generation sequencing (NGS) revealed a missense mutation, designated P.G12V, in exon 2 of the KRAS gene. Based on patients with malignant melanoma and intrahepatic cholangiocarcinoma, she received 6 cycles of GP (gemcitabine/cisplatin) combined with Camrelizumab systemic therapy, and followed by 3 cycles of Camrelizumab maintenance therapy, the efficacy was evaluated as stable disease (SD) during treatment. When the 4th cycle of Camrelizumab was suggested for maintenance therapy, the efficacy evaluation revealed that the tumor had greatly advanced. The patient refused to continue anti-tumor therapy and passed away from septic shock and multiple organ failure 3 months later. The patient had satisfactory efficacy and lived for a year after being diagnosed with two primary cancers. Despite the rarity of quadruple primary tumors and the lack of a conventional clinical management strategy, we postulate that germline mutations in the KRAS gene may be closely associated with the formation and development of multiple primary tumors. NGS testing is necessary for clinical management, and systemic treatment based on concurrent multiple main tumors is the key to improving prognosis.</p

Biocompatible Reduction and pH Dual-Responsive Core Cross-Linked Micelles Based on Multifunctional Amphiphilic Linear–Hyperbranched Copolymer for Controlled Anticancer Drug Delivery

Novel strategy has been developed for fabricating the biocompatible reduction and pH dual-responsive core cross-linked (CCL) micelles as drug delivery system (DDS) for the controlled anticancer drug delivery, via the atom transfer radical polymerization (ATRP) of <i>tert</i>-butyl acrylate (<i>t</i>BA) with <i>N</i>,<i>N</i>′-bis­(acryloyl)­cystamine (BACy) as cross-linker and a multifunctional amphiphilic linear–hyperbranched copolymer as macroinitiator, which was synthesized via the self-condensing vinyl copolymerization (SCVCP) of <i>t</i>BA and <i>p</i>-chloromethylstyrene (CMS) with a poly­(ethylene glycol) (PEG) based initiator (mPEG-Br). The hydrolyzed core cross-linked (HCCL) micelles were obtained as DDS for doxorubicin (DOX) by hydrolysis the <i>t</i>BA units into acrylic acid (AA) ones. The <i>in vitro</i> release performance showed that higher GSH concentration and/or lower pH value would lead to a faster and more efficient DOX release, meaning their reduction and pH dual-responsiveness. Therefore, the proposed HCCL micelles are expected to be potential anticancer drug-carriers for tumor microenvironment responsive controlled delivery

Flow chart of PKT206 logical model construction and analysis.

<p>Java interface programs were created to extract p53 interactions from the STRING database. We then manually curated the data and used Gene Ontology annotations to connect the network to DNA damage input and apoptosis output. CellNetAnalyzer was used for analysis and simulations, and the results were validated using literature surveys and experimental approaches including western blotting and microarray analysis.</p

Logical steady state analysis of <i>in silico</i> p53 knock-out test.

<p>The nodes with state “1” were represented in green, the nodes with state ”NaN” (un determined) were represented in orange, and the nodes with state “0” were represented in red. (A) P53 wild type when DNA damage was ”ON”; (B) P53 wild type when DNA damage was ”OFF”; (C) P53 mutant when DNA damage was ”ON”; (D) P53 mutant when DNA damage was ”OFF”.</p

Distribution of gene state alterations caused by p53 removal and DNA damage from <i>in silico</i> logical steady state analysis.

<p>The distribution of 202 p53-interacting genes with different changes between four scenarios was calculated using logical steady state analysis.</p